Published on 11 February 2025

As of 11 February 2025, the Health Technology Assessment (HTA) Council hereby makes public its preliminary recommendations on the possible financing of High Risk Human Papillomavirus (HrHPV) DNA Test and Visual Inspection with Acetic Acid (VIA) by Department of Health (DOH) and/or PhilHealth, for stakeholder feedback/comments.

These health technologies were reviewed in the light of the Philippine Food and Drug Administration (FDA) requirements for authorization, existing recommendations by the World Health Organization (WHO),  inclusion in the WHO Essential Diagnostics List (EDL), clinical practice guidelines (CPGs) [local and approved by the DOH; and international guidelines],(  and DOH Omnibus Health Guidelines (OHG), and existing economic evaluation (EE) studies. Aside from reviewing existing economic evaluation (EE) studies, costing analyses of these health technologies were performed. The supporting evidence reviewed and discussed by the HTA Council are shown in Annex A (refer to the advisory below). 

For the supporting evidence reviewed and discussed by the HTA Council, please refer to: https://bit.ly/PrelimRecomHrHPVDNATestxVIA.  

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 25 February 2025 (Tuesday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. 

Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please contact us through the same email address or via telephone call via (02) 8837 2071 local 4100.